Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 53 publications
Primary resistance to ICI-based regimens is associated with early longitudinal changes in the fecal microbiome and loss of microbial stability.
Journal: medRxiv : the preprint server for health sciences
Published: November 24, 2025
MONETTE: A Randomized Phase II Study of Ceralasertib plus Durvalumab or Ceralasertib Monotherapy in Patients with Advanced Melanoma Resistant to PD-(L)1 Inhibition.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 06, 2025
Nivolumab With or Without Ipilimumab in Patients With Recurrent or Metastatic Merkel Cell Carcinoma: A Nonrandomized, Open-Label, International, Multicenter Phase I/II Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 31, 2025
Immune-related encephalitis after immune checkpoint inhibitor therapy.
Journal: The oncologist
Published: January 29, 2024
Nivolumab + Tacrolimus + Prednisone ± Ipilimumab for Kidney Transplant Recipients With Advanced Cutaneous Cancers.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 22, 2024
Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors.
Journal: Journal for immunotherapy of cancer
Published: January 15, 2024
Nivolumab with or without ipilimumab in patients with recurrent or metastatic cervical cancer (CheckMate 358): a phase 1-2, open-label, multicohort trial.
Journal: The Lancet. Oncology
Published: April 28, 2023
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: February 07, 2023
Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 27, 2023
An Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy) in Patients with Metastatic Melanoma.
Journal: Oncoimmunology
Published: October 15, 2021
Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial.
Journal: Journal for immunotherapy of cancer
Published: March 27, 2021
Last Updated: 09/26/2026